MSKCC Experiences: Successful CAR T Collaborations With Community and International Providers

EP: 1.Highlighted Data Review of CAR-T in Early R/R MM

EP: 2.Expert Insights: Distinguishing between CARTITUDE-4 vs. KarMMa-3 Trials

EP: 3.CAR-T in R/R MM: Patient Selection & Treatment Sequencing

EP: 4.CAR-T in Earlier Lines of MM Treatment: Patient Eligibility - Considerations between Ide-cel vs. Cilta-cel

EP: 5.MSKCC Insights: CAR T Referral Process

EP: 6.Overview of the CAR T-Cell Therapy Process: Apheresis, Manufacturing, Potential Bridging Therapies, Lymphodepletion, and Infusion

EP: 7.Collaboration With Community Colleagues: Comanagement and Transitions of Care

EP: 8.CAR T Referral Process: Challenges Seen and How They Can Be Addressed

Now Viewing

EP: 9.MSKCC Experiences: Successful CAR T Collaborations With Community and International Providers

EP: 10.CAR-T Clinical Trials: Potentially Moving CAR T Into Earlier Lines of MM Treatment

EP: 11.Applying Evidence to Clinical Practice: 63-Year-Old Patient With R/R MM Post Dara-VRd Induction Scenario

EP: 12.CAR T in R/R MM: Key Takeaways and Pearls

Video content above is prompted by the following:

• Can you share any examples of successful collaborations between your academic center and community practices in the context of CAR T-cell therapy for multiple myeloma?
• Dr Usmani to ask Dr Mailankody: What are the most important lessons your institution has learned in the integration of CAR T therapy into the multiple myeloma treatment landscape?